Yalong He

Prof. Dr. Yalong He


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2018 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
AYAnan Yin
Anan Yin
NLNan Lu
Nan Lu
AEAmandine Etcheverry
Amandine Etcheverry
MAMarc Aubry
Marc Aubry
JIll S Barnholt-SloanJIll S Barnholt-Sloan
JIll S Barnholt-Sloan
YHYalong He
Yalong He
Summary: Aims: We aimed to identify a clinically useful biomarker using DNA methylation‐based information to optimize individual treatment of patients with glioblastoma (GBM).Methods: A six‐CpG panel was identified by incorporating genome‐wide DNA methylation data and clinical information of three distinct discovery sets and was combined using a risk‐score model. Different validation sets of GBMs and lower‐grade gliomas and different statistical methods were implemented for prognostic evaluation. An integrative analysis of multidimensional TCGA data was performed to molecularly characterize different risk tumors.Results: The six‐CpG risk‐score signature robustly predicted overall survival (OS) in all discovery and validation cohorts and in a treatment‐independent manner. It also predicted progression‐free survival (PFS) in available patients. The multimarker epigenetic signature was demonstrated as an independent prognosticator and had better performance than known molecular indicators such as glioma‐CpG island methylator phenotype (G‐CIMP) and proneural subtype. The defined risk subgroups were molecularly distinct; high‐risk tumors were biologically more aggressive with concordant activation of proangiogenic signaling at multimolecular levels. Accordingly, we observed better OS benefits of bevacizumab‐contained therapy to high‐risk patients in independent sets, supporting its implication in guiding usage of antiangiogenic therapy. Finally, the six‐CpG signature refined the risk classification based on G‐CIMP and MGMT methylation status.Conclusions: The novel six‐CpG signature is a robust and independent prognostic indicator for GBMs and is of promising value to improve personalized management.

7 February 2025 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
PDF file
XLXiaolin Liu
Xiaolin Liu
XLXiao Liu
Xiao Liu
XLXiaonan Luo
Xiaonan Luo
MZMaorong Zhu
Maorong Zhu
NLNannan Liu
Nannan Liu
WLWei Lin
Wei Lin
Glioblastoma (GBM) is a primary brain tumor known for its high levels of aggressiveness and resistance to current treatments such as radiotherapy and chemotherapy. As a result, there is a pressing need for innovative therapeutic approaches to combat GBM. Thus, we have developed an engineered multifunctional extracellular vesicle (EV) delivery system that offers an "all-in-one" strategy for GBM therapy. Our approach involved the use of genetic engineering to the long-lasting production of PD-1 and the brain-specific peptide angiopep-2 on the surface of EVs. These modified EVs were then utilized to rejuvenate exhausted CD8+ T cells blocking PD-L1, resulting in significant therapeutic benefits for GBM treatment. Furthermore, the EVs contained Cas9 protein and sgRNA for precise and minimally invasive gene therapy, which addressing the key barriers associated with in vivo CRISPR‒Cas9 gene editing treatment. The multigene editing of EVs resulted in efficient intratumor multisite gene editing (PLK1: 58.6%, VEGF: 52.7%), leading to the successful apoptosis of tumor cells in vivo and demonstrating an antiangiogenic effect. This research introduces a promising universal platform for combining immune checkpoint blockade therapy with gene editing treatment.

25 December 2023 in Gas Science and Engineering
Verified
Journal Article
Closed access
ZLZhiyuan Liu
Zhiyuan Liu
HZHaifeng Zhao
Haifeng Zhao
DWDongchenhao Wang
Dongchenhao Wang
PYPu Yuan
Pu Yuan
YHYalong He
Yalong He

29 June 2023 in Acta Neurochirurgica
Verified
Journal Article
Closed access
PDF file
ZZZan Zhang
Zan Zhang
SWSheng-Ju Wang
Sheng-Ju Wang
KCKun Chen
Kun Chen
AYAnan Yin
Anan Yin
WLWei Lin
Wei Lin
YHYalong He
Yalong He

1 October 2022 in Epigenomics
Verified
Journal Article
Closed access
JWJiu Wang
Jiu Wang
MZMeng Zhang
Meng Zhang
YLYi-Feng Liu
Yi-Feng Liu
YYYan Yao
Yan Yao
YJYu-Sha Ji
Yu-Sha Ji
YHYalong He
Yalong He
Aim: We aimed to identify potent CpG signatures predicting temozolomide (TMZ) response in glioblastomas (GBMs) that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methyl... Plain language summary Glioblastomas that do not have the glioma-CpG island methylator phenotype (G-CIMP) but have a methylated promoter of the MGMT gene (meMGMT) show considerable variability in t...

6 June 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
BLBowen Li
Bowen Li
JWJiu Wang
Jiu Wang
FLFangfang Liu
Fangfang Liu
RLRui Li
Rui Li
WHWeihong Hu
Weihong Hu
LWLi Wang
Li Wang
Objective. Alterations in the methylation state of pseudogenes may serve as clinically useful biomarkers of glioblastomas (GBMs) that do not have glioma-CpG island methylator phenotype (G-CIMP). Methods. Non-G-CIMP GBM datasets were included for evaluation, and a RISK-score signature was determined from the methylation state of pseudogene loci. Both bioinformatic and experimental analyses were performed for biological validation. Results. By integrating clinical information with DNA methylation microarray data, we screened a panel of eight CpGs from discovery cohorts of non-G-CIMP GBMs. Each CpG could accurately and independently predict the prognosis of patients under a treatment regime that combined radiotherapy (RT) and temozolomide (TMZ). The 8-CpG signature appeared to show opposite prognostic correlations between patients treated with RT/TMZ and those treated with RT monotherapy. The analyses further indicated that this signature had predictive value for TMZ efficacy because different survival benefits between RT/TMZ and RT therapies were observed in each risk subgroup. The incorporation of other risk factors, such as age and O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, with our pseudogene methylation signature could provide precise risk classification. In vitro experimental data revealed that two locus-specific pseudogenes (ZNF767P and CLEC4GP1) may modulate TMZ resistance via distinct mechanisms in GBM cells. Conclusion. The biologically and clinically relevant RISK-score signature, based on pseudogene methylation loci, may offer information for predicting TMZ responses of non-G-CIMP GBMs, that is independent from, but complementary to, MGMT-based approaches.